Related Experiment Video
Updated: Mar 29, 2026

12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.5K
Portosystemic Shunt Presenting as Rapidly Progressive Dementia
The Journal of the Association of Physicians of India
|November 24, 2015
Summary
Rapidly progressive dementia (RPD) in the elderly can stem from various causes. This case highlights portosystemic encephalopathy, a treatable condition, identified by specific MRI findings.
Area of Science:
- Neurology
- Gastroenterology
- Radiology
Background:
- Rapidly progressive dementia (RPD) presents a diagnostic challenge in elderly patients, necessitating a systematic clinical approach.
- Identifying the underlying cause of RPD is crucial for timely intervention and potential reversal of neurological deficits.
Observation:
- A previously healthy elderly male presented with RPD.
- The patient exhibited pallidal hyperintensities on MRI brain scans.
Findings:
- The RPD was attributed to portosystemic encephalopathy, a condition arising from a large portosystemic shunt.
- Notably, the patient maintained preserved liver function despite the shunt, underscoring the importance of considering non-liver-related causes of encephalopathy.
Implications:
- Pallidal hyperintensities on brain MRI can serve as a key diagnostic clue for portosystemic shunts in RPD patients.
- Early diagnosis of portosystemic encephalopathy allows for prompt treatment, potentially improving outcomes in elderly patients with RPD.
Related Concept Videos
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Dementia
702
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
702
Hepatic Portal System
7.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
7.8K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K

